Abstract:Abstract Funding Acknowledgements Type of funding sources: None. Background Recently, a new staging of patients with moderate to severe aortic stenosis (AS) based on extra-aortic valve cardiac damage has been described to stratify the prognostic of both, asymptomatic and symptomatic patients. Purpose To test the mid-term prognostic value of this staging system in patients with asymptomatic moderate to severe AS. Methods We analyzed a retrospective cohort of 96 patients with at least moderate AS who were systematically studied with echocardiography and cardiac magnetic resonance imaging. Patients were classified according to the staging classification of extra-aortic valve damage: no cardiac damage associated with the valve stenosis (Stage 0), left ventricular (LV) damage: LV mass index >95 g/m2 in women and >115 g/m2 in men and or E/E ́ratio >14 and/or LV ejection fraction <50% (Stage 1), mitral valve or left atrial (LA) damage: LA volume >34 ml/m2, and/or atrial fibrillation and/or ≥ moderate mitral regurgitation (Stage 2), tricuspid valve or pulmonary vasculature damage: systolic pulmonary arterial pressure ≥60 mm Hg and/or the presence of moderate or greater tricuspid regurgitation (Stage 3), or right ventricular damage: tricuspid annulus systolic velocity S ́< 9.5 cm/s, TAPSE < 17 mm, and/or RV ejection fraction < 50% (Stage 4). Given the small number of patients in Stages 3 and 4, patients were merged together in a single group. The primary endpoint was all-cause mortality during a follow-up of 5 years, regardless of whether the patient underwent aortic valve replacement. Kaplan-Meier curves and log-rank test of the time-to-death data were used. Results At baseline patients had a mean age of 70.9 years old and 71.9% were male. Most of patients had hypertension (70.8%) and dyslipidemia (55.2%). 20.8% had diabetes mellitus and only 10.4% had previous coronary artery disease. The mean transvalvular gradient was 39 ± 14 mmHg and the mean aortic valve area was 1.04 ± 0.24 cm2. According to the staging scheme, 37 patients were classified in Stage 0 (38.5%), 32 in Stage 1 (33.3%), 23 in Stage 2 (24%) and 4 in the group of Stage 3-4 (4.2%). During 5 years of follow-up, 44 patients developed symptoms (33 dyspnea, 18 angina and 5 syncope), up to 40% of patients underwent aortic valve replacement and 20 patients died (20.8%), 7 of them due to cardiovascular causes. At 5 years, there was a significant decrease in cumulative survival rates according to staging and group 2 presented the worst prognosis in our series: 95.7% in Stage 0, 81.1% in Stage 1, 75% in Stages 3-4 and 65% in Stage 2 (p = 0.04). Conclusions The novel staging scheme based in imaging evaluation of the extra-aortic [T1] cardiac damage provides mid-term prognostic information in patients with moderate to severe AS. Patients without extravalvular damage present an excellent 5-year survival, mortality increases significatively when the damage extends beyond the LV. Abstract Figure. Baseline Characteristics Abstract Figure. Survival Analysis

Staging Extramitral Cardiac Damage in Mitral Annular Calcification With Mitral Valve Dysfunction

Progression of Mild Mitral Annulus Calcification to Mitral Valve Dysfunction and Impact on Mortality

Implications of Mitral Annular Calcification on Outcomes Following Mitral Transcatheter Edge-to-Edge Repair

A Systematic Review and Meta-Analysis of Prevalence, Characteristics, and Impact of Mitral Annular Calcification on Outcomes After Transcatheter Aortic Valve Implantation

Characterizing Risks Associated With Mitral Annular Calcification in Mitral Valve Replacement

How to Manage Mitral Stenosis Due to Mitral Annular Calcification

Contemporary experience of mitral transcatheter edge‐to‐edge repair technology in patients with mitral annular calcification

Is staging for cardiac damage in aortic stenosis associated with MACE in cancer patients with prior radiotherapy or chemotherapy that underwent transcatheter aortic valve replacement?

Outcomes Following Transcatheter Mitral Valve Replacement Using Dedicated Devices in Patients With Mitral Annular Calcification

The impact of extra-valvular cardiac damage on mid-term clinical outcome following transcatheter aortic valve replacement in patients with severe aortic stenosis

High Mitral Annulus Calcium Score in Pre-Operative Chest Computerized Tomography and Adverse Outcomes in Mitral Valve Surgery

Prognostic Value of Mitral Annular Calcification in Liver Transplant Patients: Implication in Posttransplant Outcomes

Mid-term prognostic value of the novel staging of cardiac damage in asymptomatic patients with moderate to severe aortic stenosis

Staging Heart Failure Patients With Secondary Mitral Regurgitation Undergoing Transcatheter Edge-to-Edge Repair

Prognostic value of mitral annular calcification in coronary atherosclerotic disease assessed by coronary computed tomographic angiography

Mitral-specific cardiac damage score (m-CDS) predicts risk of death in functional mitral regurgitation: a study from the National Echo Database of Australia

Cardiac Damage Staging Predicts Outcomes in Aortic Valve Stenosis After Aortic Valve Replacement: Meta-Analysis

Early evolution of cardiac damage staging following transcatheter aortic valve replacement: prevalence, clinical patterns and prognostic significance

Prognostic value of extraaortic‐valvular cardiac damage in patients with moderate aortic stenosis and reduced left ventricular ejection fraction

Degenerative Mitral Stenosis by echocardiography: presentation and outcome

Utility of Multidetector Computed Tomographic Angiography as an Alternative to Transesophageal Echocardiogram for Preoperative Transcatheter Mitral Valve Repair Planning